UNSPSC 51434702: Temocaprilat

This classification denotes an ace inhibitor with the molecular formula C21H24N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D6A12Q12R, chemically known as 1,4-thiazepine-4(5h)-acetic acid, 6-((1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))- but generally known as temocaprilat, which bears US NIH Compound Identifier 71324. European Medicines Agency schedules Temocaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10885MIG.

UNSPSC 51434702 Temocaprilat, a Commodity code, identifies a specific injectable pharmaceutical used in emergency and acute-care settings. State and local governments procure this medication primarily through emergency medical services departments, hospitals, and public health agencies as part of Advanced Life Support drug protocols. The procurement involves supply agreements for specific unit quantities with strict expiration-date requirements, firm pricing inclusive of shipping and taxes, and vendor warranties covering product defects and material replacement. Issuing bodies include municipal fire-rescue departments and state health agencies operating pharmacy benefit programs. The Tampa Fire Rescue procurement reflects typical municipal emergency services purchasing: a sealed-bid IFB with line-item quantities (in this case, 1,020 units of Diltiazem 25mg vials alongside other ALS medications), firm delivery timelines, and one-year terms with renewal options. The Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs signals state-level interest in alternative sourcing and cost-management strategies for pharmaceutical supply chains, though this particular RFI targets broader pharmacy-benefit restructuring rather than Temocaprilat specifically. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals represents cooperative purchasing vehicles that aggregate demand across multiple state and local jurisdictions to achieve pricing leverage.

Recent activity centers in Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative structure extending reach to Oregon and other participating jurisdictions. The City of Tampa's 26P00188 sealed-bid opportunity (response deadline April 8, 2026, estimated value $40,000) exemplifies direct municipal procurement with SLBE sheltered-market designation and a 5 percent bid discount. The Minnesota cooperative RFP (due March 26, 2026) targets multiple awards across authorized wholesalers with two-year terms effective July 1, 2026, requiring NDC-level product specifications, cGMP and DSCSA compliance, and pricing through flat, net, or WAC-minus formats. Both opportunities impose strict product-availability, shelf-life, and pharmaceutical-compliance documentation requirements including Safety Data Sheets and accessibility conformance reporting. Vendor participation appears fragmented across municipal, state health, and cooperative purchasing vehicles rather than concentrated in a single issuing body.